Investor Relations Director
ForbionCheck size: Forbion does not publish one standard current check-size range across its funds on the official site.
Rachelle Young is listed in a Investor Relations Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
World-class science, experienced teams and differentiated products capable of producing major health or planetary outcomes.
Opportunities without a strong biotechnology, health or bioeconomy basis and credible scientific evidence are less aligned.
Present the science, validation, IP, team, development and regulatory plan, market and value-inflection milestones.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Rachelle Young is a current Investor Relations Director at Forbion, according to the firm's official roster. No additional background is inferred where the firm does not publish a biography.